Scarica l'app Stockscreener
9.075
0.01%
-0.005
Precedente Chiudi:
$9.08
Aprire:
$9.17
Volume 24 ore:
1.19M
Relative Volume:
1.03
Capitalizzazione di mercato:
$510.62M
Reddito:
$27.46M
Utile/perdita netta:
$-46.05M
Rapporto P/E:
-7.0349
EPS:
-1.29
Flusso di cassa netto:
$-33.83M
1 W Prestazione:
+1.67%
1M Prestazione:
+6.44%
6M Prestazione:
-22.86%
1 anno Prestazione:
+12.09%
Intervallo 1D:
$9.01
$9.60
Intervallo di 1 settimana:
$8.66
$9.60
Portata 52W:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Nome
Zevra Therapeutics Inc
Settore
Industria
Telefono
(321) 939-3416
Indirizzo
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Confronta ZVRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
9.07 | 511.18M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.88 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.28 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.84 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.80 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.79 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-08 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Iniziato | Guggenheim | Buy |
| 2024-09-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-24 | Reiterato | Maxim Group | Buy |
| 2024-04-02 | Reiterato | Maxim Group | Buy |
| 2024-03-12 | Iniziato | William Blair | Outperform |
| 2023-03-17 | Iniziato | Maxim Group | Buy |
Mostra tutto
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% HigherHere's What Happened - MarketBeat
Insider Buy: What is Zevra Therapeutics Incs market positionJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
Volume Recap: Will Zevra Therapeutics Inc benefit from geopolitical trendsEarnings Risk Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
The Technical Signals Behind (ZVRA) That Institutions Follow - Stock Traders Daily
Published on: 2026-01-17 12:49:06 - baoquankhu1.vn
J.P. Morgan: Zevra Sees EU As Land Of Opportunity For Miplyffa - Citeline News & Insights
Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C - MSN
Is Zevra Therapeutics (ZVRA) Using J.P. Morgan Spotlight To Reframe Its Rare-Disease Investment Story? - simplywall.st
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Zevra Therapeutics Reports Strong Q3 Earnings and Strategic Growth - MSN
Zevra Therapeutics FY 2024 Earnings Preview - MSN
Can Zevra Therapeutics Inc. stock withstand economic slowdownJuly 2025 Sentiment & Verified Entry Point Signals - ulpravda.ru
How Zevra Therapeutics Inc. stock benefits from tech adoptionJuly 2025 Rallies & Expert Approved Trade Ideas - ulpravda.ru
Can Zevra Therapeutics Inc. stock double in next 5 yearsJuly 2025 Gainers & Reliable Volume Spike Alerts - Улправда
Can Zevra Therapeutics Inc. stock sustain revenue growthTrade Performance Summary & Stock Market Timing Techniques - ulpravda.ru
Is Zevra Therapeutics Inc. stock a top pick in earnings season2025 Risk Factors & Fast Gain Swing Alerts - Улправда
Will Zevra Therapeutics Inc. stock deliver strong dividend growthWeekly Gains Report & Verified Momentum Stock Ideas - ulpravda.ru
What Wall Street predicts for Zevra Therapeutics Inc. stock priceAnalyst Downgrade & Precise Entry and Exit Recommendations - Улправда
Is Zevra Therapeutics Inc. stock a buy before product launchesWeekly Gains Summary & Weekly Stock Performance Updates - Улправда
Aug EndMonth: How Zevra Therapeutics Inc. (1GDA) stock reacts to fiscal policies2025 Price Targets & Accurate Entry and Exit Point Alerts - ulpravda.ru
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference - The Manila Times
Zevra Therapeutics to Present at J.P. Morgan 44th Annual Healthcare Conference on January 15, 2026 - Quiver Quantitative
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Precision Trading with Zevra Therapeutics Inc. (ZVRA) Risk Zones - Stock Traders Daily
Sell Signal: How Zevra Therapeutics Inc stock benefits from tech adoptionLayoff News & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Is Zevra Therapeutics (ZVRA) Using Expanded Access To Quietly Recast Its Rare-Disease Growth Story? - Sahm
TheStreet - thestreet.com
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market - Seeking Alpha
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics announces CFO transition - MSN
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics stock maintains Buy rating at H.C. Wainwright on expanded access deal - Investing.com Nigeria
ZVRA Boosts Distribution for Miplyffa with Uniphar Agreement - GuruFocus
Zevra Therapeutics executes distribution agreement to broaden access to Miplyffa for the treatment of Niemann-Pick disease type C (NPC) - marketscreener.com
Zevra Therapeutics Signs Expanded Miplyffa Distribution Deal With Uniphar - marketscreener.com
Zevra Therapeutics (ZVRA) Expands MIPLYFFA Access with Uniphar A - GuruFocus
Zevra Therapeutics Signs Expanded Access Agreement with Uniphar to Enhance Availability of MIPLYFFA® for Niemann-Pick Disease Type C Patients - Quiver Quantitative
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC) - The Manila Times
New deal expands access to a vital Niemann-Pick C treatment beyond Europe - Stock Titan
How Zevra Therapeutics Inc. (ZVRA) Affects Rotational Strategy Timing - Stock Traders Daily
Can Zevra Therapeutics Stock Hold Up When Markets Turn? - Trefis
Profit Review: How institutional buying supports Zevra Therapeutics Inc. stockJuly 2025 Trends & Long-Term Growth Stock Strategies - Улправда
Analysts’ Top Healthcare Picks: Zevra Therapeutics (ZVRA), Novan (NOVN) - The Globe and Mail
Discipline and Rules-Based Execution in ZVRA Response - Stock Traders Daily
Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? - Yahoo Finance
Is Zevra Therapeutics (ZVRA) Undervalued After Its Recent Share Price Pullback? - Yahoo Finance
Does Zevra Therapeutics Near $8 Reflect Its 92% DCF Upside Potential in 2025? - simplywall.st
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics (ZVRA) director files report showing no holdings - Stock Titan
Schroder Investment Management Group Acquires New Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics Inc Azioni (ZVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Zevra Therapeutics Inc Azioni (ZVRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McFarlane Neil F. | President and CEO |
Oct 10 '25 |
Sale |
10.82 |
19,500 |
210,908 |
222,016 |
3.19%
2.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):